Candel Therapeutics Inc (CADL)
11.10
+0.52
(+4.91%)
USD |
NASDAQ |
May 23, 10:28
Candel Therapeutics Cash from Financing (TTM): -1.376M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -1.376M |
| December 31, 2023 | -0.121M |
| September 30, 2023 | 0.036M |
| June 30, 2023 | 0.036M |
| March 31, 2023 | 0.058M |
| December 31, 2022 | 19.97M |
| September 30, 2022 | 19.94M |
| Date | Value |
|---|---|
| June 30, 2022 | 91.29M |
| March 31, 2022 | 91.60M |
| December 31, 2021 | 71.80M |
| September 30, 2021 | 71.83M |
| June 30, 2021 | 0.474M |
| March 31, 2021 | 0.601M |
| December 31, 2020 | 0.49M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.376M
Minimum
Mar 2024
91.60M
Maximum
Mar 2022
26.19M
Average
0.5455M
Median
Cash from Financing (TTM) Benchmarks
| Allurion Technologies Inc | 83.51M |
| AngioDynamics Inc | -59.25M |
| Eliem Therapeutics Inc | 0.855M |
| Macrogenics Inc | 50.49M |
| GlycoMimetics Inc | 0.0876M |